133 related articles for article (PubMed ID: 9218627)
1. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance.
Kennedy KJ; Smith WS; Miller SD; Karpus WJ
J Immunol; 1997 Jul; 159(2):1036-44. PubMed ID: 9218627
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide.
Karpus WJ; Kennedy KJ; Smith WS; Miller SD
J Neurosci Res; 1996 Aug; 45(4):410-23. PubMed ID: 8872901
[TBL] [Abstract][Full Text] [Related]
3. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis.
Whitham RH; Bourdette DN; Hashim GA; Herndon RM; Ilg RC; Vandenbark AA; Offner H
J Immunol; 1991 Jan; 146(1):101-7. PubMed ID: 1701788
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides.
Kennedy MK; Tan LJ; Dal Canto MC; Tuohy VK; Lu ZJ; Trotter JL; Miller SD
J Immunol; 1990 Feb; 144(3):909-15. PubMed ID: 1688591
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis.
Benson JM; Stuckman SS; Cox KL; Wardrop RM; Gienapp IE; Cross AH; Trotter JL; Whitacre CC
J Immunol; 1999 May; 162(10):6247-54. PubMed ID: 10229871
[TBL] [Abstract][Full Text] [Related]
6. Degenerate antigen recognition by CD4+ effector T cells in experimental autoimmune encephalomyelitis.
McRae BL; Karandikar NJ; Miller SD
J Neuroimmunol; 1997 May; 75(1-2):156-62. PubMed ID: 9143249
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes.
Vandenbark AA; Vainiene M; Ariail K; Miller SD; Offner H
J Neurosci Res; 1996 Aug; 45(4):430-8. PubMed ID: 8872903
[TBL] [Abstract][Full Text] [Related]
8. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig.
Brod SA; al-Sabbagh A; Sobel RA; Hafler DA; Weiner HL
Ann Neurol; 1991 Jun; 29(6):615-22. PubMed ID: 1716432
[TBL] [Abstract][Full Text] [Related]
9. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.
Vanderlugt CL; Rahbe SM; Elliott PJ; Dal Canto MC; Miller SD
J Autoimmun; 2000 May; 14(3):205-11. PubMed ID: 10756082
[TBL] [Abstract][Full Text] [Related]
10. Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread.
Takács K; Chandler P; Altmann DM
Eur J Immunol; 1997 Nov; 27(11):2927-34. PubMed ID: 9394820
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition.
Tan LJ; Kennedy MK; Miller SD
J Immunol; 1992 May; 148(9):2748-55. PubMed ID: 1374098
[TBL] [Abstract][Full Text] [Related]
12. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.
Vanderlugt CL; Neville KL; Nikcevich KM; Eagar TN; Bluestone JA; Miller SD
J Immunol; 2000 Jan; 164(2):670-8. PubMed ID: 10623809
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction.
Kennedy MK; Tan LJ; Dal Canto MC; Miller SD
J Immunol; 1990 Jul; 145(1):117-26. PubMed ID: 2358669
[TBL] [Abstract][Full Text] [Related]
14. Mannosylated self-peptide inhibits the development of experimental autoimmune encephalomyelitis via expansion of nonencephalitogenic T cells.
Kel JM; Slütter B; Drijfhout JW; Koning F; Nagelkerken L
J Leukoc Biol; 2008 Jul; 84(1):182-90. PubMed ID: 18424662
[TBL] [Abstract][Full Text] [Related]
15. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes.
Tan L; Gordon KB; Mueller JP; Matis LA; Miller SD
J Immunol; 1998 May; 160(9):4271-9. PubMed ID: 9574529
[TBL] [Abstract][Full Text] [Related]
16. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse.
al-Sabbagh A; Miller A; Santos LM; Weiner HL
Eur J Immunol; 1994 Sep; 24(9):2104-9. PubMed ID: 7522160
[TBL] [Abstract][Full Text] [Related]
17. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis.
McRae BL; Vanderlugt CL; Dal Canto MC; Miller SD
J Exp Med; 1995 Jul; 182(1):75-85. PubMed ID: 7540658
[TBL] [Abstract][Full Text] [Related]
18. Specific immune regulation of chronic-relapsing experimental allergic encephalomyelitis in mice.
Kennedy MK; Dal Canto MC; Trotter JL; Miller SD
J Immunol; 1988 Nov; 141(9):2986-93. PubMed ID: 2459237
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.
Elliott EA; McFarland HI; Nye SH; Cofiell R; Wilson TM; Wilkins JA; Squinto SP; Matis LA; Mueller JP
J Clin Invest; 1996 Oct; 98(7):1602-12. PubMed ID: 8833909
[TBL] [Abstract][Full Text] [Related]
20. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide.
Leadbetter EA; Bourque CR; Devaux B; Olson CD; Sunshine GH; Hirani S; Wallner BP; Smilek DE; Happ MP
J Immunol; 1998 Jul; 161(1):504-12. PubMed ID: 9647262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
